spacer
home > pmps > summer 2019 > staying ahead of the curve
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Staying Ahead of the Curve

In the grand scheme of clinical trial planning, labelling processes may seem insignificant in comparison to obvious fundamentals such as drug manufacturing, securing funding, or patient recruitment. As clinical packaging is typically approached sequentially (manufacture, package, label, ship), it is unsurprising that labelling is usually only properly considered and defined during the latter stages of the process. It is just a label after all, right?

Wrong. A label is the first thing a patient – and a regulator – will see when they receive a kit. A label is also vital in the bid to obtain approval in countries where a trial is operating. With the American Journal of Health citing that incorrect labelling is one of the top five reasons for drug recall in the US, it is time we acknowledge the real role labelling plays in the bigger picture of a clinical trial’s success.

Clinical trials are changing rapidly, and this is having a big impact on labelling processes, which need to evolve to meet increasingly complex criteria. Labels are no longer used as a basic table of contents, but they need to be multifunctional and used to deliver variable information in different formats and languages. The core drivers for change can be grouped into four categories: the emergence of biologics products, growth in global trials, increased regulation, and adaptive trials − each bringing its own set of labelling challenges.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
James McAleavey graduated from Queen’s University Belfast, UK, with a BSc honours degree in Mathematics and Computer Science. James joined Almac Clinical Services in 2002, having previously worked within the labelling industry for almost 10 years. As part of Almac’s global label services team, he is a subject matter expert on the challenges of the regulatory and design aspects of labels within a clinical trial and the key role they play in ensuring successful study and patient compliance. He has extensive experience in the auditing of label manufacturing and packaging sites throughout the world, imparting knowledge on the regulatory requirements and industry expectations.
spacer
James McAleavey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

Pharmapack Europe 2020

5-6 February 2020, Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement